Welcome to Markets Desk, your midday read on the stories moving money and markets.
RTL Group posted a strong third quarter, with headline revenue surging thirty-eight point four percent to one point eight five billion euros, though the more telling figure is the four point eight percent organic growth, which strips out acquisition noise and reflects genuine underlying momentum in the European broadcasting giant's core business.
Shifting to biotech, Akeso scored a meaningful regulatory milestone after China's National Medical Products Administration accepted its supplemental new drug application for ivonescimab combined with chemotherapy as a first-line treatment for locally advanced or metastatic biliary tract cancer, a notoriously difficult-to-treat indication with limited existing options.
And in the AI and labor conversation, Honeywell Technologies chief executive Vimal Kapur pushed back on displacement fears at the Fortune five hundred Innovation Forum in Detroit, arguing the technology is fundamentally about amplifying human productivity rather than eliminating headcount, even as C-H Robinson's chief executive cited sixty percent productivity gains already running through their logistics operations.
That's the tape. Markets Desk, signing off the floor.
